3 results
Primary objective: To demonstrate a clinically significant improvement in morning FEV1 in moderate to severe allergic asthmatics inadequately controlled by ICS therapy treated with QAW039 for 12 weeks compared to placebo.Secondary objectives:…
•To evaluate the efficacy of ASP8302 compared with placebo in subjects with Underactive Bladder (UAB)•To investigate the safety and tolerability of ASP8302 compared with placebo in subjects with UAB•To investigate the pharmacokinetics of ASP8302 in…
The primary objective of the randomized part of the protocol is to investigate if a conditioning regimen containing one alkylator (Bu) combined with two antimetabolites (Clo and Flu) results in superior 2-year acute grade III to IV-free, chronic non…